-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Vebicorvir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2090064-66-5.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 2090064-66-5 |
| Description | Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC50s from 1.84 μM to 7.3 μM. |
Product Information
| Synonyms | Vebicorvir|2090064-66-5|UNII-16F6055SMG|ABI-H0731|16F6055SMG|11-Oxo-N-((2-(trifluoromethyl)thiazol-5-yl)methyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide 5,5-dioxide|5,5,11-Trioxo-10,11-dihydro-5H-dibenzo[b,f][1,4]thiazepine-8-carboxylic acid (2-trifluoromethyl-thiazol-5-ylmethyl)-amide|Vebicorvir [INN]|Vebicorvir [USAN]|CHEMBL4650324|SCHEMBL21250344|WHO 11201|HY-109195|CS-0119137|11-Oxo-N-((2-(trifluoromethyl)thiazol-5-yl)methyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide5,5-dioxide|6,11,11-trioxo-N-[[2-(trifluoromethyl)-1,3-thiazol-5-yl]methyl]-5H-benzo[b][1,4]benzothiazepine-3-carboxamide|Dibenzo(b,F)(1,4)thiazepine-8-carboxamide, 10,11-dihydro-11-oxo-N-((2-(trifluoromethyl)-5-thiazolyl)methyl)-, 5,5-dioxide |
| IUPAC Name | 6,11,11-trioxo-N-[[2-(trifluoromethyl)-1,3-thiazol-5-yl]methyl]-5H-benzo[b][1,4]benzothiazepine-3-carboxamide |
| Molecular Weight | 467.44 |
| Molecular Formula | C19H12F3N3O4S2 |
| Canonical SMILES | C1=CC=C2C(=C1)C(=O)NC3=C(S2(=O)=O)C=CC(=C3)C(=O)NCC4=CN=C(S4)C(F)(F)F |
| InChI | InChI=1S/C19H12F3N3O4S2/c20-19(21,22)18-24-9-11(30-18)8-23-16(26)10-5-6-15-13(7-10)25-17(27)12-3-1-2-4-14(12)31(15,28)29/h1-7,9H,8H2,(H,23,26)(H,25,27) |
| InChIKey | LBJVBJYMZKEREY-UHFFFAOYSA-N |
| Boiling Point | 566.3±50.0 °C at 760 mmHg |
| Flash Point | 296.3±30.1 °C |
| Purity | 99.73% |
| Density | 1.6±0.1 g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White to off-white (Solid) |
| Application | the treatment of chronic HBV infection |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 817 |
| Exact Mass | 467.02213271 |
| Index Of Refraction | 1.619 |
| In Vitro | Vebicorvir (ABI-H0731) demonstrates inhibition of pgRNA, HBeAg, and HBsAg production, with EC50s of 2.68 μM, 4.95 μM, and 7.30 μM, respectively. Vebicorvir (ABI-H0731) is an inhibitor of pgRNA encapsidation and rcDNA synthesis. |
| In Vivo | After i.v. administration, the drug rapidly distributes and decayes in a biphasic manner in all species tested. Plasma clearance values of ABI-H0731 were 8.05, 10.1, 14.7, and 4.86 ml/min/kg, representing 9, 16, 47, and 11% of liver blood flow, in mouse, rat, dog, and monkey, respectively. |
| Target | HBV |
| Vapor Pressure | 0.0±1.5 mmHg at 25°C |
| XLogP3-AA | 2.4 |
